33 completed, 10 terminated, 4 active not recruiting, 4 withdrawn. 35 Phase 1, 27 Phase 2, 2 Phase 3.
Follow belinostat: new trials by email Literature Review of belinostat trials Research Report on belinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity Belinostat, Cisplatin, Etoposide - Carcinoma, Neuroendocrine, Tumor, Neuroendocrine | Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2026-11-02 | 2026-10-28 |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma Soquelitinib, Belinostat, Pralatrexate - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Phase 3 | Recruiting | Corvus Pharmaceuticals, Inc. | 150 | 2024-10-02 | 2026-09-25 |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Belinostat Injection, Pralatrexate Injection, CHOP - Peripheral T Cell Lymphoma | Phase 3 | Active not recruiting | Acrotech Biopharma Inc. | 504 | 2023-10-04 | 2026-10-15 |
| Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment Belinostat, Biopsy Procedure, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2023-03-01 | 2026-09-18 |
| Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma Belinostat, Durvalumab - Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma | Phase 1 | Completed | University of Utah | 7 | 2022-01-14 | 2026-10-14 |
| Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma Binimetinib, Belinostat - Metastatic Uveal Melanoma | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2021-12-15 | 2026-04-06 |
| Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics Ribociclib, Belinostat - Metastatic Breast Cancer, Recurrent Ovarian Carcinoma | Phase 1 | Terminated | University of Utah | 12 | 2021-05-03 | 2026-09-04 |
| Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer Talazoparib, Belinostat - Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Completed | University of Michigan Rogel Cancer Center | 26 | 2021-03-04 | 2025-01-23 |
| Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Azacytidine, Romidepsin, Belinostat - PTCL | Phase 2 | Recruiting | University of Virginia | 50 | 2021-02-19 | 2026-01-21 |
| Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation Belinostat, nivolumab, ipilimumab - Metastatic Adenocarcinoma | Phase 1 | Withdrawn | University of Utah | 2020-10-01 | 2020-10-28 | |
| Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma Belinostat, Biopsy Procedure, Biospecimen Collection - Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2020-09-08 | 2026-09-08 |
| Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials Belinostat, Atazanavir - Solid Tumor, Hematological Malignancies | Phase 1 | Completed | Acrotech Biopharma Inc. | 8 | 2019-08-05 | 2023-05-03 |
| Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Belinostat, Pevonedistat - Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 | Terminated | National Cancer Institute (NCI) | 18 | 2019-06-20 | 2026-03-03 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Belinostat, Zidovudine, Interferon-Alfa-2b - Adult T-cell Leukemia-Lymphoma, ATLL | Phase 2 | Completed | University of Miami | 15 | 2016-12-12 | 2026-03-10 |
| Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas volasertib, belinostat - Relapsed and Refractory Aggressive B- and T-cell Lymphomas, Lymphoma | Phase 1 | Withdrawn | Yale University | 2016-10-01 | 2017-12-22 | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma Busulfan, Caphosol, Glutamine - Lymphoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2016-06-01 | 2016-05-04 | |
| Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes Belinostat IV - Solid Tumors, Hematological Malignancies | Phase 1 | Completed | Acrotech Biopharma Inc. | 17 | 2016-04-27 | 2025-10-20 |
| To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. Belinostat - Relapsed/Refractory Solid Tumors/Hematological Malignancies | Phase 1 | Terminated | Acrotech Biopharma Inc. | 18 | 2016-03-01 | 2019-11-20 |
Showing 20 of 56. Sign in to see all of them.
Leukemia, Myeloid, Acute (6) · Lymphoma (6) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, Non-Hodgkin (6) · Lymphoma, T-Cell, Peripheral (6) · Ovarian Neoplasms (6) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5) · Lymphoma, Large-Cell, Anaplastic (5) · Lymphoma, T-Cell (5) · Lymphoma, T-Cell, Cutaneous (5) · Hematologic Neoplasms (4) · Hodgkin Disease (4) · Lung Neoplasms (4) · Lymphoma, B-Cell, Marginal Zone (4)
National Cancer Institute (NCI) (19) · Valerio Therapeutics (9) · Acrotech Biopharma Inc. (7) · University of Utah (3) · M.D. Anderson Cancer Center (2) · Spectrum Pharmaceuticals, Inc (2) · City of Hope Medical Center (1) · Corvus Pharmaceuticals, Inc. (1) · Emory University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Herlev Hospital (1) · Holy Cross Hospital, Florida (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · University of Arizona (1)
United States (48) · Denmark (7) · United Kingdom (6) · Canada (5) · Germany (5) · France (4) · Spain (3) · Hungary (2) · Israel (2) · Italy (2) · Poland (2) · Australia (1) · Belgium (1) · Croatia (1) · Netherlands (1)
Beata Holkova, MD (2) · Wasim Khan, MD (2) · Adam Lerner, MD (1) · Ahmad Tarhini, MD, PhD (1) · Amanda Cashen (1) · Amanda Cashen, MD (1) · Amit Oza (1) · Andreas Neubauer, MD (1) · Andreas Viardot, MD (1) · Andrei Shustov, MD (1) · Anish Thomas, M.D. (1)
PMID 21502553, PMID 23382909, PMID 24369094, PMID 25404094, PMID 25962426, PMID 26921086, PMID 28869931, PMID 29951694, PMID 33602316, PMID 34552007, PMID 39821392, PMID 40932107
N01CM62205 (2), N01CM62209 (2), P30CA033572 (2), U01CA062491 (2), UM1CA186644 (2), 2008 (1), F30CA206291 (1), N01CM00100 (1), N01CM17107 (1), N01CM62203 (1), P30CA014599 (1), P30CA015083 (1), P30CA023074 (1), P30CA138292 (1), R21NS100244 (1)